The Centers for Medicare & Medicaid Services has issued a permanent billing and reimbursement J-code, J9183, for the ...
UroGen Pharma’s latest analyst update keeps the fair value target effectively anchored at US$35.63, with no reset in the central valuation estimate. Bullish voices see this as support for a ...
ImmunityBio has successfully closed a $100 million financing arrangement aimed at accelerating the worldwide commercial launch of its bladder cancer treatment, ANKTIVA®. The market responded ...
Year of Clinical Validation and Strategic Expansion Across Pipeline, AI Platform Advances Towards Commercialization, and ...
Q4 2025 Earnings Call March 30, 2026 4:30 PM EDTCompany ParticipantsPanna Sharma - President, CEO & DirectorDavid Margrave ...
The biotechnology firm ImmunityBio finds itself at the center of a growing class-action lawsuit, with its legal challenges intensifying following public statements made by its founder about a key ...
Clarity Pharmaceuticals (ASX: CU6) ('Clarity' or 'Company'), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for ...
Zacks Investment Research on MSNOpinion
5 small drug stocks to buy as sector recovery gains strength
The drug and biotech sector has been in a recovery mode since mid-2025, after going through a difficult period between 2021 ...
Map open on the mutant. Original specific gravity related? Massage garlic juice will damage a worthless natural commodity. Percolator is on mesh from the carafe under the gauge test? To apices ever ...
New urinary biomarkers show promise for bladder cancer detection and recurrence prediction. Learn more about this non-invasive diagnostic approach.
According to the FDA, ImmunityBio’s communications “create a misleading impression” that Anktiva can cure or prevent cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results